Needham maintains TransMedics Group at Buy, raises price target to $110 from $106

Needham reaffirmed its Buy rating for TransMedics Group and increased its price target to $110 from $106, suggesting a 59.5% upside from the Nov 5 close of $68.98.

Original reporting
Published Nov 6, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Needham maintains TransMedics Group at Buy, raises price target to $110 from $106 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may attract short‑term interest and support the stock toward the new target.

02

Market read

Analyst target raise provides a modest bullish signal for TMED.

03

What to watch

No new product or regulatory news accompanies the target change.

Relevance 5/10Novelty 5/10Timing: today

Background

Needham maintains a Buy rating on TransMedics Group and lifts its price target by 3.8% to $110.

Market effects

May lift sentiment in the medical device sector for similar small‑cap innovators.

Limited to U.S. small‑cap investors.

Low

Counterpoint

Target raises for micro‑caps can be premature; price may already reflect optimism.

Key entities

  • TransMedics Group

    Medical device company listed on Nasdaq (TMED).

  • Needham

    Equity research firm issuing the rating and target.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.